Elekta AB (publ) (STO:EKTAB) today announced it has successfully
completed its acquisition of Nucletron, the world leader in
brachytherapy treatment planning and delivery. Through the combination
Elekta will offer a complete range of radiotherapy planning and delivery
technologies. As the market leader in Europe and with strong positions
in North America and Asia, Elekta will enhance the combined ability to
meet the clinical needs of cancer patients and health care providers
throughout the world.
“Now we have successfully completed the acquisition and we are very
enthusiastic about building a broader, stronger and highly complementary
range of cutting-edge cancer care solutions”